Quantum Biopharma (QNTM) reported a 2024 net loss of $14.9 million, narrowing from the loss of $18.2 million a year earlier.
Cash and cash equivalents were $12.1 million as of December 31, compared with $11.1 million a year earlier, the company said Friday in a statement.
A "strong balance sheet and overall progress" enabled the company to remove its "material uncertainty related to going concern" designation, according to the statement. "Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027."
The company's shares jumped 35% in recent Friday trading.
Price: 11.28, Change: +2.90, Percent Change: +34.59
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。